WuXi Biologics' stock price surged 5.28% during intraday trading on Monday, reflecting strong investor confidence in the company's growth prospects and strategic initiatives.

The pharmaceutical company continues to execute its previously announced share buyback plan of up to USD 400 million, having repurchased over 4.5 million shares across three consecutive trading days from May 27 to May 29, spending approximately HKD 150 million in aggregate. This ongoing buyback activity signals management's confidence in the company's intrinsic value and future prospects.

Further bolstering investor sentiment, WuXi Biologics disclosed that it added 69 new integrated projects in the first four months of the year while maintaining its full-year revenue growth guidance of 13% to 17% year-over-year. Additionally, the company's 18th drug product manufacturing facility has received GMP clearance and commenced operations, strengthening its end-to-end integrated capacity from drug substance to drug product. The company also held a business update conference call, providing further transparency to investors about its operational performance and strategic direction.